Pharmacological characterization of alpha1- and beta-adrenergic synergism of 5'DII activity in rat brown adipocytes.
Atso Raasmaja, David A York
Index: Arch. Physiol. Biochem. 112(1) , 23-30, (2006)
Full Text: HTML
Abstract
The role of adrenoceptor subtypes was studied in rat brown adipose tissue (BAT). The type II 5'-deiodinase (5'DII) was activated in response to simultaneous stimulation by beta3- and alpha1-adrenergic agonists, BRL 37344 or CGP 12177, and cirazoline, in brown adipocytes. Inhibition of the alpha1- and beta-adrenergic phenylephrine-stimulated 5'DII activity was obtained by the alpha1-adrenergic antagonists in the order of prazosin >/= wb 4101 > 5-methylurapidil. In comparison, the binding of [3H]prazosin to rat BAT plasma membranes was inhibited by alpha1-adrenergic antagonists in the order of prazosin > WB 4101 = benoxathian > 5-methylurapidil. Although the order of the alpha1-adrenergic competition seemed to be rather typical for the alpha1B-adrenergic receptors, a molecular analysis on adrenoceptor mRNAs should be made to confirm the exact alpha1-adrenergic subtypes at the level of brown adipocytes, since the possibility of a mixture of different receptor subtypes in brown fat cells and/or tissue may interact with the pharmacological characterization. Thus, specific alpha1- and beta-adrenoceptor subtypes participate in the regulation of 5'DII activity in the rat brown adipocytes, and therefore, an impaired alpha1- and beta-adrenergic co-work may be involved in a defective BAT function, e.g., in obese Zucker rats, too. An interesting possibility is that the decreased number of alpha1-adrenoceptors in the BAT of obese Zucker rats is due to the decrease in the alpha1B-adrenoceptor subtype which would further be involved especially in the regulation of BAT 5'DII activity.
Related Compounds
Related Articles:
2012-05-01
[J. Cardiovasc. Pharmacol. 59(5) , 413-25, (2012)]
2008-07-01
[Peptides 29(7) , 1207-15, (2008)]
2010-07-01
[Clin. Exp. Pharmacol. Physiol. 37(7) , 670-8, (2010)]
2010-03-01
[Clin. Exp. Pharmacol. Physiol. 37(3) , 350-7, (2010)]
2008-01-01
[Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 148(2) , 160-4, (2008)]